drugset / Trial / NCT00099268
Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The CELC200A2401 study has been designed in order to evaluate the hypothesis that administering the combination carbidopa/levodopa/entacapone at the time that levodopa therapy is initiated results in a decrease in the risk of the development of motor complications for patients with Parkinson's disease.
Timeline
- Start
- 2004-09
- Primary completion
- 2008-11
- Completion
- 2008-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Entacapone | Small molecule | 200 mg | Oral |
| Comparator | Carbidopa | Unknown | 12.5 mg | Oral |
| Comparator | Carbidopa | Unknown | 25 mg | Oral |
| Comparator | Levodopa | Small molecule | 50 mg | Oral |
| Comparator | Levodopa | Small molecule | 100 mg | Oral |